Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

(2021) Stefanie Kreissl et al.   Lancet Haematology

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

(2021) David J Straus et al.   Lancet Haematology

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

(2021) Umberto Ricardi et al.   Blood Advances

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

(2020) David J. Straus et al.   BLOOD

Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review

(2020) Mehul Dalal et al.   Expert Review of Hematology

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

(2020) Marc P. E. André et al.   Cancer Medicine

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma

(2020) M. S. A. Amin et al.   Clinical & Translational Oncology

Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016

(2020) Graça M. Dores et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality

(2020) Andrew M. Evens et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

(2020) David Straus et al.   LEUKEMIA & LYMPHOMA

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

(2019) René-Olivier Casasnovas et al.   LANCET ONCOLOGY

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma

(2019) Deborah M Stephens et al.   BLOOD

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

(2018) Andrea Gallamini et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

(2017) Peter Borchmann et al.   LANCET

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial

(2016) Patrice Carde et al.   JOURNAL OF CLINICAL ONCOLOGY

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

(2016) Peter Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network

(2014) Louis Bujan et al.   FERTILITY AND STERILITY

Risk of Premature Menopause After Treatment for Hodgkin’s Lymphoma

(2014) Anthony J. Swerdlow et al.   JNCI-Journal of the National Cancer Institute

Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

(2012) Karolin Behringer et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

(2011) Simonetta Viviani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

(2010) Michel Meignan et al.   LEUKEMIA & LYMPHOMA

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

(2009) Andreas Engert et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

(2008) Ezogelin Oflazoglu et al.   BRITISH JOURNAL OF HAEMATOLOGY